Animalcare Group (ANCR)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 217.00p
   
  • Change Today:
      0.000p
  • 52 Week High: 223.00
  • 52 Week Low: 166.40
  • Currency: UK Pounds
  • Shares Issued: 60.11m
  • Volume: 8,272
  • Market Cap: £130.43m

Animalcare enters collaboration with Dutch firm Orthros

By Josh White

Date: Thursday 24 Mar 2022

LONDON (ShareCast) - (Sharecast News) - Animalcare Group has entered into two early-stage agreements with Netherlands-based Orthros Medical, it announced on Thursday, focussed on the research and early development of 'VHH' antibodies.
The AIM-traded firm said under the collaboration, it had secured a global exclusive licence from Orthros for two preclinical VHH candidates, initially addressing osteoarthritis in dogs.

Additionally, it was entering into a research and development deal with Orthros Medical with the objective of adding further projects to the licence agreement.

Under the terms of the deal, Animalcare would make upfront payments to Orthros of €0.5m (£0.42m), and would fund some early research activities as part of the collaboration.

As the two licensed candidates progressed, Orthros could receive development, regulatory and commercial milestone payments up to a total of €11m, as well as single-digit royalties on net sales of the products.

The payments were expected to be paid out of the group's operating cash flow.

Animalcare said the licensed candidates would be developed as mono and combination therapy for local application in osteoarthritic joints to enable pain relief and, potentially, disease modification.

The candidate profiles were complementary to 'Daxocox', its existing COX-2 inhibitor approved for the treatment of osteoarthritis-related pain in dogs.

"This partnership represents a key building block in our long-term growth strategy," said chief executive officer Jenny Winter.

"We are keen to expand our early-stage pipeline by seeking out innovative technologies to meet evolving customer needs in a fast-growing, competitive market.

"Working with Orthros Medical, we have an exciting opportunity to build our future pain and osteoarthritis portfolio while exploring further potential of Orthros Medical's VHH technology in animals."

At 1422 GMT, shares in Animalcare Group were up 0.63% at 337.12p.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

ANCR Market Data

Currency UK Pounds
Share Price 217.00p
Change Today 0.000p
% Change 0.00 %
52 Week High 223.00
52 Week Low 166.40
Volume 8,272
Shares Issued 60.11m
Market Cap £130.43m

ANCR Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
73.48% below the market average73.48% below the market average73.48% below the market average73.48% below the market average73.48% below the market average
28.30% above the sector average28.30% above the sector average28.30% above the sector average28.30% above the sector average28.30% above the sector average
Price Trend
44.15% above the market average44.15% above the market average44.15% above the market average44.15% above the market average44.15% above the market average
78.95% above the sector average78.95% above the sector average78.95% above the sector average78.95% above the sector average78.95% above the sector average
Income
72.93% below the market average72.93% below the market average72.93% below the market average72.93% below the market average72.93% below the market average
50% below the sector average50% below the sector average50% below the sector average50% below the sector average50% below the sector average
Growth
26.81% below the market average26.81% below the market average26.81% below the market average26.81% below the market average26.81% below the market average
13.51% below the sector average13.51% below the sector average13.51% below the sector average13.51% below the sector average13.51% below the sector average

What The Brokers Say

Strong Buy 0
Buy 2
Neutral 0
Sell 0
Strong Sell 0
Total 2
buy
Broker recommendations should not be taken as investment advice, and are provided by the authorised brokers listed on this page.

ANCR Dividends

  Latest Previous
  Final Interim
Ex-Div 20-Jun-24 19-Oct-23
Paid 19-Jul-24 17-Nov-23
Amount 3.00p 2.00p

Trades for 25-Apr-2024

Time Volume / Share Price
11:08 228 @ 215.05p
09:48 5,159 @ 218.80p
09:48 685 @ 218.80p
08:03 2,200 @ 217.00p

ANCR Key Personnel

CFO Chris Brewster
CEO Jenny Winter

Top of Page